Earnings ForecastAnalysts have revised the company's future earnings outlook downward, with a lower FY24 EPS estimate and a reduced FY24 revenue estimate.
Financial SustainabilityWith a substantial monthly cash burn, the company's financial runway is in question, potentially necessitating additional funding or increased revenue to maintain operations beyond late 2024.
Regulatory ChallengesThe company is facing significant hurdles such as obtaining FDA approval and securing favorable CMS/commercial reimbursement, which are crucial for its future success.